Reported 9 months ago
Novo Nordisk (NVO) and Eli Lilly (LLY) are still considered the top two pharmaceutical stocks due to recent positive drug trial results for their GLP-1 weight-loss drugs and approval in China. Analysts believe these two companies continue to dominate the market, but other players like Amgen could emerge as interesting options in the GLP-1 market. Merck and AstraZeneca are also mentioned as solid quality names in the pharmaceutical industry to keep an eye on.
Source: YAHOO